Previsioni
Il prezzo obiettivo medio degli analisti è 5,47 € (+107,98%). La mediana è 5,47 € (+107,98%).
| Acquista |
5 |
| Mantieni |
2 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Protalix reports strong revenue and profit growth in Q2 2026, stock slightly lower premarket
Protalix increased revenue in the second quarter to $19.9 million (+26.8%) and reported a net profit of $3.8 million (EPS $0.05). Product sales were driven primarily by Elfabrio to Chiesi; the company holds $40.7 million in cash and is debt-free. Management reaffirmed the 2026 revenue guidance but noted variable ordering patterns from partners and a pipeline that is still maturing; top-line data for PRX-115 are expected in H2 2027. The stock fell modestly by 0.41% in premarket trading. » Altro su de.investing.com
Protalix beats revenue expectations but misses EPS and shares plunge
Protalix reported Q4 2025 revenue of $52.74 million versus expected $18.35 million, but missed on earnings per share at -$0.08 (forecast $0.035). The stock fell about 13% in premarket trading after the company reported a net profit swing to a $6.6 million loss for the fiscal year. Higher R&D costs (+51% to $19.6 million) and increased cost of sales weighed on profitability, while sales to Pfizer supported the strong revenue. Protalix expects a $25 million milestone payment and sees opportunities from a potential European approval of a new Elfabrio dosing regimen. » Altro su de.investing.com
Protalix partners with Secarna to develop antisense therapies for rare kidney diseases
Protalix and Secarna have entered a collaboration and option agreement to develop antisense oligonucleotide therapies for rare kidney diseases. Protalix will identify pharmaceutical targets, Secarna will use its AI platform OligoCreator to design candidate molecules, and Protalix will receive an exclusive license option for clinical development and commercialization. The agreement marks Protalix’s first expansion into rare kidney diseases using RNA technologies; financial terms were not disclosed. Protalix also reported a Q3 2025 EPS and revenue miss versus analyst expectations. » Altro su de.investing.com
Protalix misses Q3 2025 earnings forecast, stock falls sharply premarket
Protalix reported Q3 2025 earnings per share of $0.03, missing the $0.07 expectation; quarterly revenue was $17.67 million versus an estimated $17.79 million. The stock fell 13.55% in premarket trading to $1.85. For the first nine months, the company reported revenue growth of 24% to $43.6 million and held $29.4 million in cash; Protalix plans to start a phase 2 study for PRX-115 before year-end with initial results expected in Q3 2027. » Altro su de.investing.com
Protalix and Chiesi seek re-evaluation of negative EMA opinion on Elfabrio
Protalix and Chiesi Global Rare Diseases have requested a re-evaluation of the EMA’s negative opinion on the proposed alternative dosing regimen for Elfabrio. The aim is to approve an additional option of 2 mg/kg every four weeks alongside the existing 1 mg/kg every two weeks for the treatment of adult patients with Fabry disease. The current marketing authorization remains in effect during the procedure; the final decision will be made by the European Commission after the review is completed. Elfabrio carries a warning for hypersensitivity reactions; Protalix will publish quarterly results on November 17. » Altro su de.investing.com
Dati finanziari
Nell'ultimo trimestre, Protalix BioTherapeutics ha registrato ricavi pari a 19,36 Mln € e un utile netto di 3,5 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 19,36 Mln | 27,25% |
| Utile lordo | 12,4 Mln | 52,78% |
| Utile netto | 3,5 Mln | 74,26% |
| EBITDA | 4,47 Mln | 88,09% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 232,07 Mln € |
Numero di azioni | 84,32 Mln |
Massimo/minimo a 52 settimane | 2,91 € - 1,50 € |
| Dividendi | No |
Beta | 0,01 |
Rapporto P/E | 11,61 |
Rapporto PEG | -0,02 |
Rapporto P/B | 3,02 |
Rapporto P/S | 3,01 |
Profilo aziendale
Protalix BioTherapeutics, Inc., una società biofarmaceutica, si occupa dello sviluppo e della commercializzazione di proteine terapeutiche ricombinanti basate sul proprio sistema proprietario di espressione proteica su cellule vegetali ProCellEx negli Stati Uniti, in Australia, Canada, Israele, Brasile, Russia, Turchia e a livello internazionale. La società offre Elelyso per il trattamento della malattia di Gaucher. Il suo portafoglio di prodotti in sviluppo comprende PRX-102, un candidato a proteina terapeutica, che si trova nell'ultima fase di sperimentazioni cliniche per il trattamento della malattia di Fabry; PRX-110, una forma ricombinante proprietaria di desossiribonucleasi I umana espressa su cellule vegetali, che ha completato le sperimentazioni cliniche di fase IIa per il trattamento della fibrosi cistica; PRX-115, un'uricasi ricombinante PEGilata espressa su cellule vegetali per il trattamento della gotta; e PRX-119, un candidato prodotto a base di DNasi I umana ricombinante PEGilata espressa su cellule vegetali per il trattamento di malattie correlate ai NET. La società ha accordi e partnership con Pfizer, Fundação Oswaldo Cruz (Fiocruz) e Chiesi Farmaceutici S.p.A. La società è stata fondata nel 1993 e ha sede a Hackensack, nel New Jersey.
| Nome | Protalix BioTherapeutics |
| CEO | Dror Bashan |
| Sede centrale | Hackensack,
nj Israele |
| Sito web | |
| Settore | Beni di prima necessità |
| Industria | Prodotti alimentari |
| Quotazione in borsa | 15/05/1998 |
| Dipendenti | 226 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
AMEX | PLX |
Frankfurt | PBDA.F |
Düsseldorf | PBDA.DU |
München | PBDA.MU |